Acorda Therapeutics Inc (ACOR.OQ)
18 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||President,Chief Executive Officer, Director|
|49||2014||Chief Technology Officer and Site Head|
|59||2016||Chief Business Operations, Principal Accounting Officer|
|66||2004||Chief Scientific Officer|
|61||2012||President - International, General Counsel, Corporate Secretary|
- BRIEF-FDA Says Making List Of Cos Blocking Access To Samples Of Branded Products
- BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14
- BRIEF-Acorda Files Marketing Authorization Application For Inbrija
- BRIEF-Acorda Enters Into Cooperation Agreement With Scopia
- BRIEF-Acorda Announces FDA Acceptance Of New Drug Application For Inbrija